degarelix
Overview
Degarelix is a GnRH (gonadotropin-releasing hormone) receptor antagonist that rapidly suppresses LH, FSH, and testosterone without an initial testosterone surge. It is FDA-approved for androgen deprivation therapy (ADT) in advanced prostate cancer, offering faster testosterone suppression than GnRH agonists. In the MSK-CHORD dataset it appears as a recorded systemic therapy for prostate cancer patients.
Evidence in the corpus
- Degarelix is listed as a tracked systemic therapy drug in the MSK-CHORD (msk_chord_2024) dataset covering 3,211 PRAD patients. NLP-based annotation of prior treatment history (using transformer models) identified patients who had received degarelix, enabling post-treatment alteration enrichment analyses including AR and TP53 enrichment after prior systemic therapy in prostate cancer. PMID:39506116
Resistance mechanisms
- AR and TP53 alterations are enriched in PRAD patients after prior systemic therapy (NLP-annotated), consistent with known escape mechanisms from androgen deprivation including GnRH-receptor antagonists such as degarelix. PMID:39506116
Cancer types (linked)
- PRAD — prostate cancer; androgen deprivation therapy documented in MSK-CHORD cohort.
Sources
- PMID:39506116 — Al Shihabi et al. (Nature 2024). MSK-CHORD clinicogenomic dataset; degarelix recorded as androgen deprivation therapy for prostate cancer patients.
This page was processed by crosslinker on 2026-04-30.